Molecular determinants of response to high-dose androgen therapy in prostate cancer
Clinical trials of high-dose androgen (HDA) therapy for prostate cancer (PC) have shown promising efficacy but are limited by lack of criteria to identify likely responders. To elucidate factors that govern the growth-repressive effects of HDAs, we applied an unbiased integrative approach using genetic screens and transcriptional profiling of PC cells with or without demonstrated phenotypic sensitivity to androgen-mediated growth repression. Through this comprehensive analysis, we identified genetic events and related signaling networks that determine the response to both HDA and androgen withdrawal. We applied these findings to develop a gene signature that may serve as an early indicator of treatment response and identify men with tumors that are amenable to HDA therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
JCI insight - 4(2019), 19 vom: 03. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nyquist, Michael D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.10.2020 Date Revised 13.10.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1172/jci.insight.129715 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301123365 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301123365 | ||
| 003 | DE-627 | ||
| 005 | 20231225103958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/jci.insight.129715 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1003.xml |
| 035 | |a (DE-627)NLM301123365 | ||
| 035 | |a (NLM)31503550 | ||
| 035 | |a (PII)129715 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nyquist, Michael D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular determinants of response to high-dose androgen therapy in prostate cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2020 | ||
| 500 | |a Date Revised 13.10.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Clinical trials of high-dose androgen (HDA) therapy for prostate cancer (PC) have shown promising efficacy but are limited by lack of criteria to identify likely responders. To elucidate factors that govern the growth-repressive effects of HDAs, we applied an unbiased integrative approach using genetic screens and transcriptional profiling of PC cells with or without demonstrated phenotypic sensitivity to androgen-mediated growth repression. Through this comprehensive analysis, we identified genetic events and related signaling networks that determine the response to both HDA and androgen withdrawal. We applied these findings to develop a gene signature that may serve as an early indicator of treatment response and identify men with tumors that are amenable to HDA therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Genetics | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a Tumor suppressors | |
| 650 | 7 | |a Androgens |2 NLM | |
| 650 | 7 | |a RB1 protein, human |2 NLM | |
| 650 | 7 | |a Retinoblastoma Binding Proteins |2 NLM | |
| 650 | 7 | |a Ubiquitin-Protein Ligases |2 NLM | |
| 650 | 7 | |a EC 2.3.2.27 |2 NLM | |
| 700 | 1 | |a Corella, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamad, Osama |e verfasserin |4 aut | |
| 700 | 1 | |a Coleman, Ilsa |e verfasserin |4 aut | |
| 700 | 1 | |a Kaipainen, Arja |e verfasserin |4 aut | |
| 700 | 1 | |a Kuppers, Daniel A |e verfasserin |4 aut | |
| 700 | 1 | |a Lucas, Jared M |e verfasserin |4 aut | |
| 700 | 1 | |a Paddison, Patrick J |e verfasserin |4 aut | |
| 700 | 1 | |a Plymate, Stephen R |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Peter S |e verfasserin |4 aut | |
| 700 | 1 | |a Mostaghel, Elahe A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCI insight |d 2016 |g 4(2019), 19 vom: 03. Okt. |w (DE-627)NLM257703918 |x 2379-3708 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2019 |g number:19 |g day:03 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/jci.insight.129715 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2019 |e 19 |b 03 |c 10 | ||